These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 14594906)

  • 41. Cellular basis of drug-induced torsades de pointes.
    Roden DM
    Br J Pharmacol; 2008 Aug; 154(7):1502-7. PubMed ID: 18552874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing predictors of drug-induced torsade de pointes.
    Belardinelli L; Antzelevitch C; Vos MA
    Trends Pharmacol Sci; 2003 Dec; 24(12):619-25. PubMed ID: 14654302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [QT prolongation and torsade de pointes--tachycardia in therapy with maprotiline].
    Züchner H
    Dtsch Med Wochenschr; 2002 May; 127(18):983-4. PubMed ID: 11987023
    [No Abstract]   [Full Text] [Related]  

  • 44. QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.
    Manini AF; Raspberry D; Hoffman RS; Nelson LS
    J Med Toxicol; 2007 Dec; 3(4):178-81. PubMed ID: 18072173
    [No Abstract]   [Full Text] [Related]  

  • 45. Terfenadine should be withdrawn from clinical use.
    Khilnani G
    J Assoc Physicians India; 1999 Sep; 47(9):943. PubMed ID: 10778682
    [No Abstract]   [Full Text] [Related]  

  • 46. Torsade de pointes associated with rupatadine.
    Fité-Mora R
    Rev Esp Cardiol; 2009 Mar; 62(3):330-1; author reply 332. PubMed ID: 19268083
    [No Abstract]   [Full Text] [Related]  

  • 47. Long QT syndrome caused by noncardiac drugs.
    Viskin S; Justo D; Halkin A; Zeltser D
    Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consideration of the JT interval rather than the QT interval.
    Salik J; Muskin PR
    Psychosomatics; 2013; 54(5):502. PubMed ID: 24034531
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug-induced long QT syndrome in women.
    Li G; Cheng G; Wu J; Zhou X; Liu P; Sun C
    Adv Ther; 2013 Sep; 30(9):793-802. PubMed ID: 24085659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-induced QT prolongation: consequences and current dilemma.
    Dubrey SW; Grocott-Mason R
    Br J Hosp Med (Lond); 2007 Jan; 68(1):50-1. PubMed ID: 17260721
    [No Abstract]   [Full Text] [Related]  

  • 51. [Torsade de pointes: a new way to kill drugs].
    Tamargo Menéndez LJ
    An R Acad Nac Med (Madr); 1998; 115(1):23-42; discussion 42-6. PubMed ID: 9741134
    [No Abstract]   [Full Text] [Related]  

  • 52. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
    Letsas KP; Efremidis M; Sideris A
    Int J Cardiol; 2008 Mar; 124(3):366-7; author reply 368-9. PubMed ID: 17400314
    [No Abstract]   [Full Text] [Related]  

  • 53. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes.
    Roden DM
    Pacing Clin Electrophysiol; 1998 May; 21(5):1029-34. PubMed ID: 9604234
    [No Abstract]   [Full Text] [Related]  

  • 55. Drug-induced prolongation of the QT interval: why the regulatory concern?
    Shah RR
    Fundam Clin Pharmacol; 2002 Apr; 16(2):119-24. PubMed ID: 12031064
    [No Abstract]   [Full Text] [Related]  

  • 56. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ
    Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.
    Smithburger PL; Seybert AL; Armahizer MJ; Kane-Gill SL
    Expert Opin Drug Saf; 2010 Sep; 9(5):699-712. PubMed ID: 20377471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding torsade de pointes: a bridge to tailored drug therapy?
    Tan HL; Wilde AA
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):87-8. PubMed ID: 12090899
    [No Abstract]   [Full Text] [Related]  

  • 60. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.